Changes in generations of PAMAM dendrimers and compositions of nucleic acid nanoparticles govern delivery and immune recognition
A dynamic microscale mid-throughput fibrosis model to investigate the effects of different ratios of cardiomyocytes and fibroblasts
TheWell Bioscience
TheWell Bioscience provides xeno-free, 3D cell culture solutions, empowering research in organoids, regenerative medicine, and drug discovery.
VoxCell BioInnovation
VoxCell BioInnovation is a forward-thinking biotechnology company specializing in 3D, vascularized bioprinted tissue models for preclinical drug screening. Using high-resolution bioprinting, trade vascularization software, and Universal Bioinks™, VoxCell creates human-like tumor models that mimic the tumor microenvironment, enhancing drug testing accuracy.
Bioprinting Laboratories
Bioprinting Labs’ pillar/perfusion plates enable robust and reproducible organoid culture and in situ analysis. Our products streamline organoid-based assays by facilitating miniature organoid culture and enhancing organoid maturity through dynamic culture in the pillar/perfusion plates.
AIM Biotech
AIM Biotech is a leading bioengineering company, offering scalable, cost-effective 3D cell culture platforms, drug screening services, and customized assay development. By combining model realism and platform simplicity, AIM’s plug-and-play technologies empower drug developers to mimic human biology with precision, delivering clinically-relevant data.
Nilogen Oncosystems
Provision of untouched intact tumor tissue platform to allow for the investigation of clinical relevant biomarkers, mechanism of action, safety and efficacy of therapeutics.
Akita by Finnadvance
Our AKITA high-throughput microfluidic platform is compatible with standard laboratory equipment to supports a wide range of applications from compound screening to basic research. It elicits the modeling & monitoring of biological processes in healthy and diseased states.
Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.